Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

Final evaluation determination

Final evaluation determination document (PDF 295 KB)

Public committee slides (PDF 1.08 MB)

Committee papers (PDF 1.47 MB)

Evaluation consultation: 1

Evaluation consultation document (PDF 282 KB)

Committee papers (PDF 4.86 MB)

Public committee slides November 2021 (PDF 1.41 MB)

Evaluation consultation document (Online commenting)

Equality impact assessment (Scoping) (PDF 129 KB)

Final scope (PDF 200 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 293 KB)

Final stakeholder list (PDF 186 KB)

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

Draft matrix post referral (PDF 184 KB)

Draft scope post referral (PDF 232 KB)